Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study

Arsene Mekinian[1], Noémie Abisror[1], Chloé Mcavoy[1], Claire Ribet[2], Roberta Lorenzon[2,4],Eric Vicaut[3], Michelle Rosenzwajg[2,4] and David Klatzmann[2,4]*

Affiliation

[1]AP-HP, Saint Antoine Hospital, Internal Medicine Department, F-75012, Paris, France

[2]AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), F-75651, Paris, France

[3]AP-HP, Saint Louis/Lariboisière Hospitals, Unité de recherche clinique and Université Paris 7, F-75010, Paris, France.

[4]Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (i3); F-75651, Paris, France

Keywords: T cells, abortion, immunotherapy, biotherapy

Article type: Research Article

Running head: Low-dose interleukin-2 in recurrent early pregnancy loss

Word count in the main body of the manuscript: 2033words

Word count in the abstract: 261 words

Number of references: 41

3 tables

2 color figures

*Corresponding Author:

Prof. D. Klatzmann, Pitié-Salpêtrière Hospital, Clinical Investigation Center for Biotherapies and Immunology-Immunopathology-Immunotherapy laboratory, 83 Bd de l'Hôpital, F-75013, Paris, France. E-mail: david.klatzmann@sorbonne-universite.fr Phone: +33 1 42 17 74 61.

Abstract

Background: Regulatory T cells (Tregs) are essential for maternal-fetal tolerance, and their deficiency has been implicated in immune-mediated pregnancy loss. Low-dose interleukin-2 (IL-2$_{LD}$) selectively expands and activates Tregs and has shown efficacy in murine models of spontaneous immune-mediated miscarriage. This proof-of-concept study assessed the safety and efficacy of IL-2$_{LD}$ in women with unexplained recurrent early pregnancy loss (uREPL).

Methods: In the FACIL-2 open-label trial (NCT03970954), 15 women with ≥5 prior uREPLs received 3 MIU/day of IL-2 for 5 days per cycle, starting 10 days after menses onset. Up to five cycles were administered if pregnancy was not achieved. Treg frequency was measured by flow cytometry, and clinical outcomes were recorded. An additional 9 patients with similar profiles were treated under compassionate use without immunomonitoring.

Results: In FACIL-2 participants, IL-2$_{LD}$ significantly increased circulating Tregs, with a mean 2.0-fold rise at day-8 (p<0.001), primary endpoint reached) and a sustained elevation at day-29. Among the eight pregnancies, four were viable at 12 weeks, resulting in three live births and one late miscarriage at 20 weeks. Successful pregnancies were associated with greater Treg expansion (day-0 to day-8: 2.87 vs. 1.64-fold, p=0.03; day-0 to day-29: 1.71 vs. 1.24-fold, p=0.008). In the compassionate group, five pregnancies yielded two live births. All newborns were healthy. Safety signals were generally mild and manageable.

Interpretation: IL-2$_{LD}$ safely expanded Tregs and achieved a 46% rate of viable pregnancies in a high-risk population, and despite the short treatment duration. These results support the further investigation of IL-2$_{LD}$ as an immunotherapy for uREPL in a controlled trial with extended treatment through early gestation.

INTRODUCTION

Recurrent early pregnancy loss (REPL), defined as the loss of three or more pregnancies before 14 weeks of amenorrhea, affects approximately 3–5% of women of reproductive age [1]. While REPL may result from anatomical, genetic, hormonal, infectious, or thrombophilic causes, a substantial proportion of cases remain unexplained after standard evaluation—these are termed unexplained REPL (uREPL). In women with five or more prior losses, the likelihood that miscarriage is due to fetal aneuploidy diminishes significantly—from 63% after two losses to 39% after five. This shift increases the probability of maternal causes, notably immune dysregulation leading to reduced tolerance to the fetus [1].

Immune-mediated uREPL is thought to result from an imbalance between effector T cells (Teffs) and regulatory T cells (Tregs), disrupting maternal-fetal tolerance [2–4]. Multiple studies have reported increased Th1 and Th17 responses, elevated cytotoxic activity, and reduced anti-inflammatory cytokine production in the blood and endometrium of women with REPL[4–7]. In addition, a decrease in Tregs cells in the blood and endometrium and a reduced capacity to secrete IL-10 and TGF-β have been observed in these patients [2,4,8,9].

The role of Tregs in implementing maternal-fetal tolerance and preventing immune rejection of the embryo or fetus is further substantiated by the observation that Tregs-depleted mice reject allogeneic fetuses, whereas adoptive transfer of Tregs promotes fetus survival [10–15]. Furthermore, a rare population of uterine-resident Tregs have been shown to have trophic functions that support fetal growth [16]. The role of Tregs in pregnancy is also supported by the observation that normal pregnancy is accompanied by an increase in maternal Tregs[17].

These findings position Treg insufficiency as a plausible therapeutic target in immune-mediated uREPL. Low-dose interleukin-2 (IL-2$_{LD}$) has emerged as a potent and selective

activator of Tregs in humans, with proven safety and clinical efficacy in autoimmune diseases [18–29]. Notably, while high dose IL-2 regimens stimulate Teffs and NK cells, low-dose IL-2 regimens specifically promote Treg expansion and function, without affecting effector responses[30]. In the CBA/J x DBA/2J mouse mating combination, a classical murine model for recurrent spontaneous abortion due to Treg deficiency, IL-2$_{LD}$ has been shown to mitigate infertility and restore the normal pregnancy rate[11,31].

Building on these findings, we conducted the FACIL-2 open-label proof-of-concept trial to evaluate the immunological and clinical impact of IL-2$_{LD}$ in women with severe uREPL. We hypothesized that peri-implantation IL-2$_{LD}$ would enhance maternal Treg responses and improve pregnancy outcomes in this high-risk population.

METHODS

FACIL-2 study design, participants and treatment

FACIL-2 was an open monocentric proof-of-concept trial evaluating the tolerance and the efficacy of IL-2$_{LD}$ in women with REPL. The study was approved by the institutional review board CPP Ile de France III and performed in accordance with the Declaration of Helsinki and good clinical practices. FACIL-2 is registered as "*Low-dose Interleukin-2 in Women With Unexplained Miscarriages*" with ClinicalTrials number NCT03970954.

Patients were recruited from January 2021 to July 2023 and were treated and followed up at the Saint Antoine hospital in Paris. The main inclusion criteria were: women from 18 to 40 years old with at least 5 consecutive recurrent early pregnancy loss before 14 weeks of amenorrhea and unexplained after the usual check-up; volunteer to participate in the trial and having given written consent after appropriate information. The main exclusion criteria

were: uterine or pelvic abnormality: uterine malformation, intracavitary fibroid, synechiae, polyp, hydrosalpinx; balanced translocations in both spouses; type I or II diabetes; Sickle cell disease; constitutional or acquired thrombophilia or autoimmunity (protein deficit C, S, ATIII, homozygous factor V or II deficiency, antiphospholipid syndrome, antithyroid antibodies positive, celiac disease, hyperhomocysteinemia); decreased ovarian reserve (anti-mullerian hormone (AMH) <1 ng/ml); antral follicular counts (AFC) < 4 (**table S1**)

Among 18 included patients for the study, 15 were treated with IL-2$_{LD}$ (**Figure 1**). Written informed consent was obtained from all participants before enrolment in the study. Patients received IL-2$_{LD}$ in the form of Aldesleukin (Proleukin® 18 MIU, Novartis Pharma SAS, Rueil-Malmaison, France) provided by the central pharmacy of the Assistance Publique-Hôpitaux de Paris and diluted to the dose of 3MIU/injection (or lower in case of dose reduction) by a pharmacist.

Participants were first monitored and immunophenotyped during an untreated cycle. For the next cycle, they were administered 3 million international units (MIU) of IL-2 daily for 5 consecutive days, starting 10 days after the onset of menses (day 1) (**Figure S1**). At this dose, a 5-day injection course maintains a Treg expansion for about a month [18]. This regimen was timed so that IL-2 would be cleared by the potential time of embryo implantation, given a half-life of subcutaneaous IL-2 of about 4 hours and an embryo implantation at 6 to 10 days after ovulation, corresponding to days 20 to 24 of the standard menstrual cycle. If pregnancy was not achieved (β-HCG negative on day 29), a new treatment cycle was started, with a maximum of 5 cycles (**Figure S1**). Treatment cycles were planned as consecutive, but an interruption of up to two cycles was allowed. The dose of IL-2 could be decreased in case of side effects, but to no less than 1MIU/day.

Immunomonitoring

The immune status of the FACIL-2 patients was assessed during the first untreated cycle and the subsequent IL-2$_{LD}$ cycles. Blood samples were obtained for immunological tests immediately before the administration of IL-2$_{LD}$. Sample were obtained daily from day 10 to day 14, and at day 17 and day 29 of each cycle. All the immunomonitoring procedures were performed as previously described and are described in the Supplementary methods[23,32–34].

Outcomes

The primary endpoint of the study was the increase in Treg count on day 14 of the first treatment cycle compared to baseline (day 10 of the untreated cycle). The secondary endpoints were the number of full-term pregnancies and safety assessed by the biological and clinical adverse events of the mother, fetus and newborn up to 6 weeks of age.

Statistical analysis

Changes in Tregs between baseline and the other follow up timepoint were analyzed throughout the treatment period by non-parametric ANCOVA for repeated measurements, using baseline values as covariable (Conover method). Data are presented as mean ± SEM. Normal distribution of each set of variables was analysed by D'Agostino & Pearson omnibus normality test. Student's t-test for normally distributed data and non-parametric Mann–Whitney were used to compare variables as appropriate. Paired data comparing follow-up time points to baseline value were analysed using Student's t-test for normally distributed data and paired Wilcoxon signed-rank test for nonparametric. A p value < 0.05 was considered significant. Statistical analyses were performed using GraphPad Prism version 10.0 (GraphPad Software, San Diego, CA, USA).

Compassionate use of IL-2$_{LD}$ in REPL

During the same period, nine additional women who were unable or unwilling to participate in the FACIL-2 trial received the same IL-2$_{LD}$ treatment on a compassionate use. They also had a history of at least 5 uREPLs before 14 weeks of gestation. These patients did not have the planned visits of the FACIL-2 study and had no biological follow up nor enforced safety follow up.

All patients treated at any AP-HP hospital (the body that oversees all public hospitals in the Paris region) are informed that data obtained during their care may be used for research purposes. Patients have the right to opt out if they wish. The nine additional patients mentioned did not opt out and are not included in a research protocol. The pregnancy outcome results that we report are from their care.

RESULTS

Overall study design and Patients

Fifteen women were enrolled in the FACIL-2 trial and completed a baseline (untreated) menstrual cycle followed by at least one IL-2$_{LD}$ treatment cycle (**Figure 1**). Of these, 9 received a second cycle, 3 a third one, 2 a fourth one and 1 a fifth one. The reason for discontinuation of the treatment was either pregnancy, patient preference or having missed more than 2 treated cycles. In parallel, 9 patients were treated on a compassionate basis (**Figure 1**). Compassionate-use patients were not eligible for FACIL-2 due to exclusion criteria (e.g., age >40, autoimmune comorbidities) or declined trial participation due to logistical

constraints. Of note, 2 of these patients were initially enrolled in FACIL-2 and were excluded from the trial after the first and the third cycle of IL-2$_{LD}$, respectively, because they had a discontinuation of their treatment for more than 2 cycles. Of these 9 patients, 7 received a second cycle, 4 a third and 1 a fourth.

Inclusion criteria were consistent across both cohorts: women aged 18–40 with ≥5 uREPLs before 14 weeks of gestation. All these patients were treated with the same treatment modalities. Only the FACIL-2 patients were followed clinically, biologically and for safety. Baseline characteristics of both groups are shown in Table 1.

Treg response to IL-2$_{LD}$

Before receiving their first IL-2 treatment cycle, FACIL-2 patients were monitored during an untreated cycle. Mean Tregs proportion remained relatively stable during this follow up, but with a slight but significant increase of Tregs percentage from 7.93±1.66 at day 10 to 8.49±1.72 at day 14 (p=0.016) (**Figure 2A**).

In contrast, there was a marked Treg response to IL-2$_{LD}$ during all treated cycle (**Figure 2B**).

During the first 5 days of the first treatment cycle, there was a small decrease of mean Treg proportions in the blood indicative of a Treg recirculation, as previously reported[22]. This was then followed by an increase that peaked at day-17 (8 days after treatment initiation), also as already noted[23,26], with an overall 2.01±0.24 mean fold increase of mean Treg proportion (p<0.001). Thus, the primary criteria of the study has been reached. Of note, the increase persisted up to day-29 with a 1.33±0.24 fold increase. There was some heterogeneity in the response (**Figure S2**), as already reported[21,25]. These observations concerning the percentage of circulating Tregs were also true for their absolute number (**Figure 2C**). For the 2nd cycle of treatment, the kinetic of the effect was similar, but both the peak value at day-17 (2.47±0.76

fold) and the persisting increase at day-29 (1.55±0.40 fold) were slightly higher than for the 1st cycle (**Figure 2B**). This was also true for the 3rd cycle, and there were not enough patients going through the 4th and 5th cycle to draw conclusions (**Figure 2B**).

$IL-2_{LD}$ also activated the expanded Tregs as shown by an increase of CD25 expression (**Figure 2D**)[35,23,25,34]. As there was no effect on effector T cells, the expansion of Tregs translated in a marked increase in the Treg/Teff ratio (**Figure 2E**).

Clinical outcomes

In FACIL-2 participants, out of eight pregnancies, four were viable at 14 weeks, resulting in three live births and one late miscarriage at 20 weeks for a rupture of menbranes. In the compassionate use group, five pregnancies resulted in two live births. All the born babies were in good health, with an APGAR score of ≥9 at 5 and 10 minutes.

There were no differences in the number of previous uREPL or in baseline Treg levels between the FACIL-2 patients who had viable and non-viable pregnancies (**Table 2**).

Notably, the levels of Treg activation and expansion appeared to be higher in patients who had successful pregnancies, with a Treg fold increase of 2.84 ± 0.51 vs. 1.83 ± 0.51 (p=0.03) at day-17. Moreover, the duration of the effect was also more pronouced with a Treg fold increase of 1.71 ± 0.34 vs 1.24 ± 0.09 (p= 0.008) on day-29, the end of the first cycle. (**Table 2 and Figure 2F.**

Safety

There was a total number of 17 reported SAEs (**Table 3**). Of these 10 were deemed related to the IL-2 treatment. They were all observed at the dose of 3MIU of IL-2. There were two Hepatic cytolysis and two Flu-like syndromes with one associated with biological inflammation. Of note, six patients experienced cardiac symptoms including thoracic pain and/or EKG abnormalities (n=3 at 3MIU and n=3 at 1.5MIU). To our knowledge, such cardiac symptoms have never been reported in the many hundreds of patients with autoimmune diseases treated with IL-2, usually at dose ≤2MIU. These side effects led to the reduction of the IL-2 dose used to 1.5 or 1 MIU/injection. For one patient treatment was discontinued because of the EKG modification showing negative T waves.

There was a total 149 NSAE reported, with 127 deemed related to IL-2. For these later, 93 were Grade 1, 33 were Grade 2, and 1 was Grade 3. Of these, 105 were observed at the dose of 3MIU and 22 at the dose of 1.5 or 1 MIU (**Table 3**).

There were no adverse events for the fetus and there was no reported AEs during the baby follow-up, which occurred at 2, 3 and 6months.

Table 1. Demographic, clinical and biological characteristics

	FACIL-2 (n=15)	Compassionate (n=9)
Age (years) (mean±sd) (range)	34.5 ± 3.85 (26-39)	36.8 ± 4.9 (26-41)
BMI	29.1 ± 5.5 (20-41)	24.0±3.5 (19-31)
Diabetes (n; %)	0 (0%)	0 (0%)
Active tobacco (n; %)	3 (20%)	1 (11%)
Alcohol (n;%)	0 (0%)	0 (0%)
Obstetric history		
Nulliparity **(n;%)**	12 (80%)	4 (44%)
Number of previous miscarriages (mean ± sd) (range)	6.4 ± 1.9 (5-10)	7.4 ± 3.24(5-15)
History of live birth (n; %)	3 (20%)	5 (56%)
Anti-mullerian hormone level at baseline (ng/mL) (mean ± sd) (range)	2.85 ± 2.0 (1-8.2)	4.98 ± 7.14 (1.1-23.6)
Antral follicular counts at baseline(ng/mL) (mean ± sd) (range)	20.85 ± 13.92 (7-55)	14.67 ± 8.40 (6-34)
Number of previous treated pregnancies Progesterone Steroids LMWH and aspirin	1 1 2	2 1 2
IL-2$_{LD}$ treatment		
Number of cycles of IL2 received: mean (range)	2 ±1.19 (1-5)	2.3 ± 10 (1-4)
Total dose of IL2 received (MIU): mean (range)	23.3 ± 13.24 (9-54)	33.06 ± 19.41 (7.5-69)
Pregnancy outcomes	8 (53%)	5 (55%)
Pregnancies ending before 12 WA (n;%)	4 (26%)	3 (33%)
Pregnancies continuing after 12WA (n;%)	4 (26%)	2 (22%)
Late miscarriages (13-20WG) (n;%)	1 (0.6%)	0 (0%)
Lives births (n;%)	3 (20%)	2 (22%)
Biology		
% Treg/CD4 (mean, range)	8.01 (6.37-10.11)	NA
Treg/mm3 (mean, range)	77.38 (49.41-153.9)	NA

Tableau 2: clinical and biological outcomes in patients with succesfull pregnancy and pregnancy loss.

Pregnancy	< 14 Week (N = 4)	≥ 14 Week (N = 4)	p
Age at the pregnancy	33.28±0.66	35.35±1.97	ns
AFC	31.0 ±18.02	11.5 ± 6.34 (n=2)	ns
AMH	3.25±1.64	3.02±1.60	ns
Number of previous early pregnancy loss	7.25	6.75	ns
Number of cycles of IL2 received: mean (range)	1.75±0.5 (1-2)	1.75±0.5 (1-2)	ns
Total dose of IL2 received (MIU): mean (range)	17.13±9.06 (9-30)	24.0 ±7.3 (15-30)	ns
Tregs at Baseline (mean ± sd; range)	8.16±2.82 (5.07-9.91)	7.41±1.19 (6.0-8.89)	ns
Tregs at entry in the first IL-2 cycle (mean ± sd; range)	8.43±1.58 (6.64-10.47)	7.32±1.33 (5.61-8.67)	ns
Tregs fold increase at day-8 of the first and second cycle (pooled values)	1.81±0.51	2.84±0.51	0.03
Tregs fold increase at day-29 of the first and second cycle (pooled value)	1.24±0.09	1.71±0.34	0.008

Table 3: Safety

	Nb Events (N° Patients) [% administrations]	Nb Events 3MUI (N° Patients)	Nb Events 1,5/1MUI (N° Patients)
Nb of patients treated	15		
Nb of injections administered	138 (15)		
Serious Adverse events (SAE)	**17 (10) [12,3%]**		
SAE related to Proleukin® :	10 (7) [7,2%]	7 (6)	3 (3)
Cardiac symptoms (thoracic pain and /or EKG abnomarlities)	6 (4)	3 (3)	3 (3)
Hepatic cytolysis	2 (2)	2 (2)	0
Influenza-like syndrome	1 (1)	1 (1)	0
Biological inflammatory syndrome associated with influenza-like syndrom	1 (1)	1 (1)	0
Non Serious Adverse events (NSAE)	**149 (15) [108%]**		
NSAE related to Proleukin® :	127 (15) [92%]	105 (15)	22 (4)
Grade 1 (73,2%)	93 [67,4%]	74 (14)	19 (3)
Grade 2 (25,6%)	33 [23,9%]	30 (12)	3 (2)
Grade 3* (7,8%)	1* [0,7%]	1 (1)	0
Most common NSAE related to treatment			
Injection-site reactions	45 (11) [32,6%]	37 11)	8 (2)
Others AEs among which :	82 (15) [59,4%]	68 (15)	14 (4)
Gastrointestinal symptoms	21 (10) [15,2%]	18 (9)	3 (2)
Influenza-like syndrome	19 (10) [13,8%]	16 (10)	3 (2)
Hypereosinophilia	6 (6) [4,3%]	4 (4)	2 (2)
Mucocutaneous reactions	6 (4) [4,3%]	6 (4)	0
Biological inflammatory syndrome	5 (4) [3,6%]	5 (4)	0
Cardiac symptoms (thoracic pain, dyspnea, palpitations)	4 (4) [2,9%]	3 (3)	1 (1)
Musculoskeletal pain	4 (3) [2,9%]	1 (1)	3 (2)
Asthenia	3 (2) [2,2%]	2 (2)	1 (1)
Headache	3 (3) [2,2%]	2 (2)	1 (1)
Infection	3 (2) [2,2%]	3 (2)	0
Malaise	2 (2) [1,4%]	2 (2)	0
Fever	1 (1) [0,7%]	1 (1)	0
Hypokalemia*	1* (1) [0,7%]	1 (1)	0
Hepatic cytolysis	1 (1) [0,7%]	1 (1)	0
Loss of appetite	1 (1) [0,7%]	1 (1)	0
Hand paresthesia	1 (1) [0,7%]	1 (1)	0
Hot flushes	1 (1) [0,7%]	1 (1)	0

*hypokalemia corresponding to grade 3 NSAE

Discussion

Recurrent early pregnancy loss remains a major clinical challenge, particularly in cases where standard evaluations fail to identify a cause[36]. Here, we report the first human trial suggesting that low-dose IL-2 therapy can restore immune tolerance and improve pregnancy outcomes in women with unexplained REPL.

The rationale for this approach stems from accumulating evidence that immune dysregulation—specifically, Treg insuficiency—contributes to fetal rejection in uREPL. In animal models, Tregs are critical for establishing maternal-fetal tolerance. Ablation of Tregs in mice leads to increase rate of abortion[13,37,14,11]. Conversly, Treg activation and expansion by IL-2$_{LD}$ has been shown to prevent fetal loss in the classical murine model of spontaneous abortion of DBA/2xCBA/J mating [11,31,38]. In humans, a decrease in Tregs cells in the blood and endometrium and a reduced capacity to secrete IL-10 and TGF-β have been observed in women with uREPL [2,4,8,9]. Thus, expanding and activating Tregs during early pregnancy appears as a valid therapeutic target for uREPL. Moreover, any positive outcome of such treatment will contribute to establish Treg insuficiency as a major determinant of uREPL.

Our study demonstrates for that IL-2$_{LD}$ can safely expand and activate Tregs during the peri-implantation window. The primary efficacy criteria of the study - the increase of Treg proportion at day-14 that peak at day-17 of the first cycle - was successfully met. Indeed, 5 consecutive days of IL-2 at 3MIU led to robust and significant Treg expansion, with an average 2-fold increase by day 8 after treatment initiation. Such increase, as well as the initial decrease of Treg values during the first 2-3 days, is in agreement with the effects of similar dose of IL-2$_{LD}$ in patients with other conditions and in healthy

volunteers[18,21,35,25,23,39,27,26,28,29]. Thus, Tregs from pateints with uREPL respond normaly to IL-2$_{LD.}$

In this proof of concept study, we chose to treat patients for only 5 days starting at day 10 of the menstrual cycle. Indeed, as IL-2 has initially been approved for treating advanced cancers, it has not been subjected to a formal genotoxicity study. Although genotoxicity for a natural molecule is very unlikely, it appeared preferable to not expose embryos to IL-2. As the half-life of IL-2 is of about 4 hours, and the implantation of the embryo at day 20 to 24, the administered IL-2 would have been washed out before implantation. However, the duration of the biologic effect on Tregs being much longer that its half life, the Treg stimulation was expected to cover about 2 to 4 weeks after the last injection. Although we would have liked to cover the entire first trimester of pregnancy, this schedule of administration appeared as a safe one for a first administration in this clinical setting. We indeed observed that during the first cycle, the effects on Tregs lasted for at least 4 weeks, with increased values at day-29 and at day-10 of the next cycle. This expansion of Tregs was accompanied by their activation as evaluated by the level of CD25 epression, a well known marker of Treg activation. The activation level increased everyday during treatment, and rapidely vanished as already reported. Altogether, patient with uREPL respond to IL-2$_{LD}$ as do all others[18–21,35,23,25,39,26,28,29,24] .

Some patients had reduction of their IL-2 dosage to 1.5 or 1MIU/injection due to tolerance issues (see below). This mostly occurred at different time points of treatment, although mostly after the first cycle of treatment. The heterogeneity of the IL-2 dose adjustment (dose and time) does not allow to draw conclusion such as to the compared effects of different IL-2 dosage in the context of uREPL treatment.

In previous studies, we evaluated the safety and efficacy of Treg activation by dose of IL-2 up to 3MIU. Although the effects of 3MIU were stronger and lasted longer [18,21,35], we therafter used IL-2 mostly at dose up to 2MIU because of a better tolerance. Indeed, IL-2 has a favorable safety profile at all dose up to 3MIU/injection, with mostly mild AEs, but there are still more AEs at the 3MIU dosage[21,40] . Here we started at 3MIU to maximise the duration of the effect, which is does dependant, and had to decrease the dosage in 7 patients. While most adverse events were mild and expected [40,41], transient cardiac symptoms in a subset of patients receiving 3 MIU/day were unanticipated and not observed in previous IL-2$_{LD}$ trials for autoimmune diseases. The etiology remains unclear but prompted a dose adjustment to 1.5–1 MIU/day without apparent loss of efficacy on Treg effects.

Despite the advanced disease severity—each woman having experienced ≥5 losses (range, 5-10)—the viable pregnancy rate in FACIL-2 reached 50%, with no apparent adverse effects on fetal development. There was 1/2 successful pregnancies during the first cycle and 3/6 during the second cyle. Importantly, succesfull pregnancy was associated with a significantly higher effect on Treg expansion, indicating that successful outcome of the pregnancy is indeed linked to target engagement. Moreover, the higher Treg expansion in successful pregnancy was significant up to day-29. This suggest that longer treatment duration could be beneficial.

When taking into account the compassionate use of IL-2 in a similar population, the pregnancy success rate is overall of 46%. As it is believed that about half of the uREPL do not have a immunological origin, this is a remarquable finding. This is particularly encouraging

given that the intervention was both brief and not continued during gestation, a precautionary strategy that now warrants reconsideration given the therapy's safety profile. The observation that the higher Treg expansion in successful pregnancy was significant up to day-29 support that longer treatment duration could be beneficial. Longer treatment duration will also allow using lower doses of IL-2 (1-1.5MIU) that have a better safety profile. Whether ongoing IL-2$_{LD}$ treatment through the first trimester might further improve outcomes is a compelling hypothesis for future trials.

This study has several limitations. First, the open-label design and lack of a control group preclude definitive conclusions on efficacy. Second, the small sample size limits generalizability. Third, Treg profiling was not performed in the compassionate-use group. Finally, while IL-2$_{LD}$ likely addresses an immune cause of miscarriage, not all uREPL cases are immunological, which may dilute apparent efficacy.

Despite these limitations, our results establish proof of principle that immunotherapy with IL-2$_{LD}$ can restore maternal-fetal tolerance and lead to successful pregnancies in a high-risk population. A randomized, placebo-controlled trial of IL-2$_{LD}$ administration extending into early pregnancy is now warranted to confirm efficacy and identify predictors of response.

Declaration of interests

MR and DK are inventors of patent applications related to the therapeutic use of IL-2$_{LD}$, which belongs to their academic institutions. No other potential conflicts of interest relevant to this article were reported.

Funding: Assistance Publique-Hôpitaux de Paris and the French National Research Agency (ANR-16-RHUS-0001,RHU IMAP).

Acknowledgement

We thank the patients for their participation in the trial and the personnel of the Pitié-Salpêtrière Clinical Investigation Center for Biotherapies (CIC-BTi), Michèle Barbié, Natalie Féry, Catherine Ferrapie, Nadia Graffin, Aurélie Marc, for their excellent technical assistance.

Authors' contribution to the current study:

DK conceived and supervised the study.
AM, EV, MR and DK designed the clinical study.
NA, CM, CR and RL performed the clinical follow-up of patients under the supervision of AM.
MR supervised the immunomonitoring.
AM analysed the clinical results.
MR and DK analysed the biological results.
MR and DK wrote the first draft of the manuscript that was edited by all authors.

REFERENCES

REFERENCES

Mekinian A, Cohen J, Alijotas-Reig J, *et al.* Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? *American J Rep Immunol* 2016; **76**: 8–28.

Lee SK, Kim JY, Hur SE, *et al.* An imbalance in interleukin-17-producing T and Foxp3+ regulatory T cells in women with idiopathic recurrent pregnancy loss. *Human Reproduction* 2011; **26**: 2964–71.

Nakashima A, Ito M, Yoneda S, Shiozaki A, Hidaka T, Saito S. SHORT COMMUNICATION: Circulating and Decidual Th17 Cell Levels in Healthy Pregnancy. *American J Rep Immunol* 2010; **63**: 104–9.

Wang W-J, Hao C-F, Yi-Lin, *et al.* Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients. *Journal of Reproductive Immunology* 2010; **84**: 164–70.

Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J. Expression of Intracellular Th1 and Th2 Cytokines in Women with Recurrent Spontaneous Abortion, Implantation Failures after IVF/ET or Normal Pregnancy. *American J Rep Immunol* 2002; **48**: 77–86.

Lee SK, Na BJ, Kim JY, *et al.* Determination of Clinical Cellular Immune Markers in Women with Recurrent Pregnancy Loss. *Am J Reprod Immunol* 2013; : n/a-n/a.

Nakagawa R, Muroyama R, Saeki C, *et al.* CD4+ T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T cell receptor repertoires. *Hepatol Res* 2019; published online Jan 28. DOI:10.1111/hepr.13318.

Bao SH, Wang XP, De Lin Q, Wang WJ, Yin GJ, Qiu LH. Decidual CD4+CD25+CD127dim/– regulatory T cells in patients with unexplained recurrent spontaneous miscarriage. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2011; **155**: 94–8.

Sasaki Y. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. *Molecular Human Reproduction* 2004; **10**: 347–53.

Darrasse-Jèze G, Darasse-Jèze G, Klatzmann D, Charlotte F, Salomon BL, Cohen JL. CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. *Immunol Lett* 2006; **102**: 106–9.

Chen T, Darrasse-Jeze G, Bergot AS, *et al.* Self-specific memory regulatory T cells protect embryos at implantation in mice. *J Immunol* 2013; **191**: 2273–81.

Churlaud G, Jimenez V, Ruberte J, *et al.* Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. *Clinical Immunology* 2014; **151**: 114–26.

Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. *Nat Immunol* 2004; **5**: 266–71.

Shima T, Sasaki Y, Itoh M, *et al.* Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice. *Journal of Reproductive Immunology* 2010; **85**: 121–9.

Nehar-Belaid D, Courau T, Dérian N, Florez L, Ruocco MG, Klatzmann D. Regulatory T Cells Orchestrate Similar Immune Evasion of Fetuses and Tumors in Mice. *The Journal of Immunology* 2016; **196**: 678–90.

Florez LM, Fourcade G, Darrassse-Jèze G, et al. Tissue-resident uterine regulatory T cells support fetal growth. 2023; : 2023.09.07.554921.

Amouyal C, Klatzmann D, Tibi E, et al. Pregnant type 1 diabetes women with rises in C-peptide display higher levels of regulatory T cells: A pilot study. *Diabetes & Metabolism* 2020; : 101188.

Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. *N Engl J Med* 2011; **365**: 2067–77.

Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. *N Engl J Med* 2011; **365**: 2055–66.

Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. *Science translational medicine* 2013; **5**: 179ra43.

Hartemann A, Bensimon G, Payan C, et al. Low-dose Interleukin-2 induces regulatory T cells and is well tolerated in patients with type-1 diabetes: results of a phase I/II randomized, double-blind, placebo-controlled trial. *Lancet Diabetes & Endocrinology* 2013; **1**: 295–305.

Rosenzwajg M, Six A, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in patients with type 1 diabetes. *Sci Transl Med* sumitted.

Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. *Ann Rheum Dis* 2019; **78**: 209–17.

He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis* 2020; **79**: 141–9.

Rosenzwajg M, Salet R, Lorenzon R, et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. *Diabetologia* 2020; **63**: 1808–21.

Lorenzon R, Ribet C, Pitoiset F, et al. The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial. *Journal of Autoimmunity* 2024; **144**: 103172.

Louapre C, Rosenzwajg M, Golse M, et al. A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis. Journal of Neurology. 2023; published online in review.

Rosenzwajg M, Gherasim A, Dietsch F, et al. Low-dose IL-2 in birch pollen allergy: A phase-2 randomized double-blind placebo-controlled trial. *J Allergy Clin Immunol* 2024; : S0091-6749(24)01181-3.

Leboyer M, Foiselle M, Tchitchek N, et al. Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial. *Brain, Behavior, and Immunity* 2025; **123**: 177–84.

Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. Revisiting IL-2: Biology and therapeutic prospects. *Sci Immunol* 2018; **3**: eaat1482.

Churlaud G, Jimenez V, Ruberte J, *et al.* Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. *Clin Immunol* 2014; **151**: 114–26.

Pitoiset F, Barbié M, Monneret G, *et al.* A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials. *Cytometry B Clin Cytom* 2018; published online Jan 6. DOI:10.1002/cyto.b.21622.

Pitoiset F, Cassard L, El Soufi K, *et al.* Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. *Cytometry A* 2018; **93**: 793–802.

Louapre C, Belin L, Marot S, *et al.* Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization. *European Journal of Neurology*; **n/a**. DOI:10.1111/ene.15925.

Rosenzwajg M, Churlaud G, Mallone R, *et al.* Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. *J Autoimmun* 2015; **58**: 48–58.

Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent pregnancy loss. *Nat Rev Dis Primers* 2020; **6**: 98.

Darrasse-Jèze G, Darasse-Jèze G, Klatzmann D, Charlotte F, Salomon BL, Cohen JL. CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. *Immunol Lett* 2006; **102**: 106–9.

Ruocco MG, Chaouat G, Florez L, Bensussan A, Klatzmann D. Regulatory T-cells in pregnancy: historical perspective, state of the art, and burning questions. *Front Immunol* 2014; **5**: 389.

Humrich JY, Cacoub P, Rosenzwajg M, *et al.* Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. *Ann Rheum Dis* 2022; : annrheumdis-2022-222501.

Mahmoudpour SH, Jankowski M, Valerio L, *et al.* Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. *Sci Rep* 2019; **9**: 7145.

Kolios AGA, Tsokos GC, Klatzmann D. Interleukin-2 and regulatory T cells in rheumatic diseases. *Nat Rev Rheumatol* 2021; **17**: 749–66.

Figure 1: Trial Profile

Patients with RPL treated with $IL2_{LD}$ in Facil2 & off-protocol

Figure 2: Changes in Regulatory (Treg) and Effector T cells (Teff) during IL-2_LD treatment

FIGURES LEGEND

Figure 1: Trial Profile

Figure 2: Changes in Regulatory (Treg) and Effector T cells (Teff) during IL-2_LD treatment

Treg cells were identified within the CD4$^+$ T cell population as CD25^hiCD127$^{lo/-}$Foxp3$^+$ cells. (A–F) Changes from baseline are shown as either individual curves or as mean ± SEM: **(A)** Individual curves of Treg percentages among CD4$^+$ T cells during the first treatment-free cycle, with the red line representing the mean across all patients; **(B)** Treg percentages among CD4$^+$ T cells over the full follow-up period under IL-2$_{LD}$ treatment; **(C)** Absolute counts of Tregs; **(D)** CD25 MFI in Tregs; **(E)** Tregs to Teffs ratio; **(F)** Comparison of Treg percentages during the first two treatment cycles stratified by pregnancy outcome: successful pregnancy (>12 WA, red, n = 4), early pregnancy loss (<12 weeks, blue, n = 4), and no pregnancy (green, n = 7).Statistical comparisons during follow-up were conducted using t-tests or Mann–Whitney tests, depending on data distribution (*p<0.05; **p<0.01; ***p<0.001).